vTv Therapeutics, Inc.:
Data-in hand from two Ph. 2 Diabetes (T2) trials: 1. Glucokinase Activator (TTP399); 2. Oral GLP-1r (TTP273). Evaluating TTP399 as an add-on therapy to insulin therapy in a 12 week phase 1/2 trial in patients with type 1 diabetes. Recently licensed rights to its PDE4 program to Newsoara Biopharma to further its development in China and other Pacific Rim companies as a potential therapeutic for COPD. Analyzing recent Azeliragon phase 3 data in order to move development of the therapy forward. Results from a subgroup analysis of the STEADFAST Alzheimer’s trial to be presented at CTAD discussing the effect of Azeliragon in patients with Dementia and Diabetes.
4170 Mendenhall Oaks Parkway
High Point, NC 27265
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Stock Market Data
Market Data copyright © 2017 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by